AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process
MONTREAL, Aug. 15, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that EPKINLY is now listed on the Ontario Health (Cancer…
